UPC APP 8392/2024
EP2196231 · System for ambulatory drug infusion comprising a filling apparatus for flexible containers
- Case details
- Status—ActionProcedural applicationCategoryOther procedural
- Parties
- Claimants
- Tandem Diabetes Care, Inc.Operating co.
- Tandem Diabetes Care Europe B.V.Operating co.
Representatives- Charlotte Garnitsch-Taylor Wessing
- Wim Maas-Taylor Wessing
- Alexander Rubusch-Taylor Wessing
Respondents- Roche Diabetes Care GmbHOperating co.
Representatives- Christof Augenstein-Kather Augenstein
- Katharina Brandt-Kather Augenstein
- Robert Knaps-Kather Augenstein
- Thomas Kronbergersupporting-Grünecker Patent- und Rechtsanwälte PartGmbH
- Division
- Paris CD
- Judges
- Technology
- InstrumentsMedical technology
- Language
- —
- First decided
- Feb 20, 2024
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Paris CD | Locked |
| Judge Paolo Catallozzi | Locked |
At the UPC: Tandem Diabetes Care Group (18 cases)·Roche Group (29 cases)
This dispute contains 9 other proceedings
UPC CoA 120/2025·UPC CFI 11/2025·UPC CFI 88/2024·UPC CFI 454/2023·UPC CFI 455/2023 and 4 more
1 other defendants litigating the same or a related patent
- 2024-02-20
Summary: Order of the Paris Central Division (judge-rapporteur) granting Roche Diabetes Care GmbH's application for extension of the deadline for filing its defence in a non-infringement declaration action brought by Tandem Diabetes Care (EP 2 196 231). Roche had filed a preliminary objection disputing jurisdiction which had not yet been decided; it argued it would be unreasonable to finalise a defence that might become unnecessary. The court extended the deadline to 8 April 2024, finding the extension was justified to await the preliminary objection decision, particularly given the parallel revocation action pending before the same court.
Show the legal issues (3)
- Extension of time for filing defence pending preliminary objection
- Interaction between preliminary objection proceedings and main defence deadline
- Parallel revocation action considerations
- B07D02FA56A2B9665A82CA04377664C5_en.pdf2024-02-20EN